**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Alexandros Briasoulis, MD, Amyloidosis Center, Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens

**Main Body of the Abstract**
Introduction: Hematologic response to treatment for light chain cardiac amyloidosis (AL-CA) improves myocardial function and outcomes. We evaluated changes and prognostic value of echocardiographic myocardial deformation and work in response to treatment for AL-CA.
Methods: Sixty-one patients treated for AL were enrolled and underwent echocardiographic assessment at baseline and at 1-year. Patients were stratified according to hematologic response as complete or not complete responders.
Results: A significant reduction in median NT-proBNP, posterior wall thickness (PWT), and an increase in global work index (GWI) (1,115 to 1,356 mmHg%; p = 0.018) was observed at 1-year. Patients with complete response (CR) had a more pronounced decrease in intraventricular septum thickness (14.2 to 12.0 mm; p = 0.006), improved global longitudinal strain (GLS) (-11.6 to -13.1%; p for interaction = 0.045), increased global constructive work (1,245 to 1,436 mmHg%; p = 0.008) and global work index (926 to 1250 mmHg%, p = 0.002) compared to non-CR. Furthermore, deltaGLS (ρspearman = 0.35; p < 0.001) and deltaGWI (ρspearman = -0.32; p = 0.02) correlated with delta NT-proBNP. Importantly, patients with GLS and GWI response had a better prognosis (log-rank p = 0.048 and log-rank p = 0.007, respectively). After adjustment for Mayo stage, gender, and response status, deltaGLS (HR = 1.404, p = 0.046 per 1% increase) and deltaGWI (HR = 0.996, p = 0.042 per 1mmHg% increase) were independent predictors of survival.
Conclusions: Complete hematologic response significantly improves left ventricular myocardial work indices and their change is associated with improved survival in AL-CA.



**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Alexandros Briasoulis, MD, Amyloidosis Center, Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens

**Main Body of the Abstract**
**Introduction: **Hematologic response to treatment for light chain cardiac amyloidosis (AL-CA) improves myocardial function and outcomes. We evaluated changes and prognostic value of echocardiographic myocardial deformation and work in response to treatment for AL-CA.
**Methods:** Sixty-one patients treated for AL were enrolled and underwent echocardiographic assessment at baseline and at 1-year. Patients were stratified according to hematologic response as complete or not complete responders.
**Results:** A significant reduction in median NT-proBNP, posterior wall thickness (PWT), and an increase in global work index (GWI) (1,115 to 1,356 mmHg%; p = 0.018) was observed at 1-year. Patients with complete response (CR) had a more pronounced decrease in intraventricular septum thickness (14.2 to 12.0 mm; p = 0.006), improved global longitudinal strain (GLS) (-11.6 to -13.1%; p for interaction = 0.045), increased global constructive work (1,245 to 1,436 mmHg%; p = 0.008) and global work index (926 to 1250 mmHg%, p = 0.002) compared to non-CR. Furthermore, deltaGLS (ρspearman = 0.35; p < 0.001) and deltaGWI (ρspearman = -0.32; p = 0.02) correlated with delta NT-proBNP. Importantly, patients with GLS and GWI response had a better prognosis (log-rank p = 0.048 and log-rank p = 0.007, respectively). After adjustment for Mayo stage, gender, and response status, deltaGLS (HR = 1.404, p = 0.046 per 1% increase) and deltaGWI (HR = 0.996, p = 0.042 per 1mmHg% increase) were independent predictors of survival.
**Conclusions: **Complete hematologic response significantly improves left ventricular myocardial work indices and their change is associated with improved survival in AL-CA.



 Left ventricular myocardial work improves in response to treatment and is associated with survival among patients with light chain cardiac amyloidosis PB102 (#100)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.